Literature DB >> 33046515

Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen.

Yurina Ogawa1, Yohei Masugi1,2, Tokiya Abe1, Ken Yamazaki1, Akihisa Ueno1, Yoko Fujii-Nishimura1,3, Shutaro Hori4, Hiroshi Yagi4, Yuta Abe4, Minoru Kitago4, Michiie Sakamoto5.   

Abstract

PURPOSE: Cancer-associated fibroblasts have emerged to be highly heterogenous and can play multifaceted roles in dictating pancreatic ductal adenocarcinoma (PDAC) progression, immunosuppression, and therapeutic response, highlighting the need for a deeper understanding of stromal heterogeneity between patients and even within a single tumor. We hypothesized that image analysis of fibroblast subpopulations and collagen in PDAC tissues might guide stroma-based patient stratification to predict clinical outcomes and tumor characteristics. EXPERIMENTAL
DESIGN: A novel multiplex IHC-based image analysis system was established to digitally differentiate fibroblast subpopulations. Using whole-tissue slides from 215 treatment-naïve PDACs, we performed concurrent quantification of principal fibroblast subpopulations and collagen and defined three stroma types: collagen-rich stroma, fibroblast activation protein α (FAP)-dominant fibroblast-rich stroma, and α smooth muscle actin (ACTA2)-dominant fibroblast-rich stroma. These stroma types were assessed for the associations with cancer-specific survival by multivariable Cox regression analyses and with clinicopathologic factors, including CD8+ cell density.
RESULTS: FAP-dominant fibroblasts and ACTA2-dominant fibroblasts represented the principal distinct fibroblast subpopulations in tumor stroma. Stroma types were associated with patient survival, SMAD4 status, and transcriptome signatures. Compared with FAP-dominant fibroblast-rich stroma, collagen-rich stroma correlated with prolonged survival [HR, 0.57; 95% confidence interval (CI), 0.33-0.99], while ACTA2-dominant fibroblast-rich stroma exhibited poorer prognosis (HR, 1.65; 95% CI, 1.06-2.58). FAP-dominant fibroblast-rich stroma was additionally characterized by restricted CD8+ cell infiltrates and intense neutrophil infiltration.
CONCLUSIONS: This study identified three distinct stroma types differentially associated with survival, immunity, and molecular features, thereby underscoring the importance of stromal heterogeneity in subtyping pancreatic cancers and supporting the development of antistromal therapies. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33046515     DOI: 10.1158/1078-0432.CCR-20-2298

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.

Authors:  Yan Zhao; Yueping Liu; Yunlong Jia; Xiaoxiao Wang; Jiankun He; Shuman Zhen; Jiali Wang; Lihua Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-11       Impact factor: 4.322

Review 2.  The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities.

Authors:  Yohei Masugi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma.

Authors:  Song Han; Dongtao Fu; Gerik W Tushoski; Lingsong Meng; Kelly M Herremans; Andrea N Riner; Thomas J Geoge; Zhiguang Huo; Steven J Hughes
Journal:  Theranostics       Date:  2022-06-27       Impact factor: 11.600

4.  Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.

Authors:  Stephanie L Slania; Deepankar Das; Ala Lisok; Yong Du; Zirui Jiang; Ronnie C Mease; Steven P Rowe; Sridhar Nimmagadda; Xing Yang; Martin G Pomper
Journal:  J Med Chem       Date:  2021-03-17       Impact factor: 8.039

5.  Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging.

Authors:  Esther Strating; Emma Wassenaar; Mathijs Verhagen; Paulien Rauwerdink; Susanne van Schelven; Ignace de Hingh; Inne Borel Rinkes; Djamila Boerma; Arjen Witkamp; Miangela Lacle; Riccardo Fodde; Richard Volckmann; Jan Koster; Kris Stedingk; Frederik Giesel; Remmert de Roos; Alex Poot; Guus Bol; Marnix Lam; Sjoerd Elias; Onno Kranenburg
Journal:  Br J Cancer       Date:  2022-03-16       Impact factor: 9.075

6.  Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies.

Authors:  Ryan R Kawalerski; Steven D Leach; Luisa F Escobar-Hoyos
Journal:  Oncotarget       Date:  2021-03-16

7.  Cancer-Associated Fibroblast Subgroups Showing Differential Promoting Effect on HNSCC Progression.

Authors:  Soo Hyun Kang; Su Young Oh; Heon-Jin Lee; Tae-Geon Kwon; Jin-Wook Kim; Sung-Tak Lee; So-Young Choi; Su-Hyung Hong
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

8.  Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.

Authors:  Yi-Jiang Song; Yanyang Xu; Chuangzhong Deng; Xiaojun Zhu; Jianchang Fu; Hongmin Chen; Jinchang Lu; Huaiyuan Xu; Guohui Song; Qinglian Tang; Jin Wang
Journal:  Front Immunol       Date:  2021-04-20       Impact factor: 7.561

9.  Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer.

Authors:  Tyler MacNeil; Ioannis A Vathiotis; Saba Shafi; Thazin Nwe Aung; Jon Zugazagoitia; Aaron M Gruver; Kyla Driscoll; David L Rimm
Journal:  Cancers (Basel)       Date:  2021-11-02       Impact factor: 6.639

10.  Integrated Analysis Reveals ENDOU as a Biomarker in Head and Neck Squamous Cell Carcinoma Progression.

Authors:  Chengzhi Xu; Yunbin Zhang; Yupeng Shen; Yong Shi; Ming Zhang; Liang Zhou
Journal:  Front Oncol       Date:  2021-02-05       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.